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Patrick and Lindstrom (1) reported that rabbits developed weakness, reversible
by anticholinesterases, after repeated immunization with acetylcholine receptor
(AChR)' protein purified from electric eel . This observation suggested a potential
experimental animal model for myasthenia gravis (MG) and provided the first
experimental support for the hypothesis proposed by Simpson (2), and Lennon
and Carnegie (3), that defective neuromuscular transmission in MG may be
caused by antibody blocking AChR at motor end plates .
We report in this paper the establishment in rats and guinea pigs of
experimental autoimmune myasthenia gravis (EAMG), a reproducible model dis-
ease based on the Patrick-Lindstrom observation . We will describe its clinical
picture and preliminary immunological and electrophysiological observations .
The effects of blockade of receptors in vivo by specific toxin will be compared
with findings in EAMG, and similarities between EAMG and MG will be
detailed .
Materials and Methods
Preparation ofAChR .
￿
AChR protein from the main electric organs of Electrophorus electricus
and Torpedo californica were purified by a slight modification ofthemethod ofLindstromandPatrick
(4) employing affinity chromatography on a conjugate of cobra toxin (Naja naja siamensis) coupled to
agarose . The concentration of AChR protein is expressed as moles of toxin-binding sites per liter .
AChR is a multimer containing two to three toxin-binding sites (4). A crude extract of rat muscle
AChR was prepared for antibody studies by extraction of a membrane pellet with Triton X-100
solutions as described elsewhere.'
Inoculation of Animals.
￿
74 female Lewis rats (obtained from Microbiological Associates, Inc.,
Bethesda, Md .) and 30 outbred female albino guinea pigs, both aged approximately 10 wk, were
injected with graded doses of eel AChR . Sevenguinea pigs received 600 pmol of TorpedoAChR. Both
noninoculated animals and animals inoculated only with adjuvants were used as controls . All rats
* Supported by grants from the National Institutes of Health (1-ROl-NS-AI-11719-01 and NS
11323-02), the National Multiple Sclerosis Society (RG-948-A-2), and the Muscular Dystrophy
Association of America.
`Abbreviations used in this paper: AChR; acetylcholine . receptor, CFA, complete Freund's
adjuvant ; EAMG, experimental autoimmune myasthenia gravis ; EMG, electromyograph; MG,
myasthenia gravis.
' Lindstrom, J . M., V . A. Lennon, M. E. Seybold, and S. Wittingham . Antibodies specific for
human muscle acetylcholine receptors found in serum from myasthenia gravis patients . Manuscript
submitted for publication .
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were premedicated with Tylosin (Eli Lilly & Co ., Indianapolis, Ind.) for 1 wk before inoculation
because of endemic chronic respiratory disease .
Because difficulties were encountered in emulsifying the AChR protein, especially with doses
greater than 110 pmol, several methods of preparing both antigen and complete Freund's adjuvant
(CFA) were employed in different experiments . In early studies (all guinea pig experiments and
approximately one-third of the total rat experiments) stock solutions of AChR were diluted in
phosphate-buffered saline (pH 7.4) . In later studies emulsification was improved considerably by
aggregating AChR by dialysis against water, allowing removal of excess Triton from the supernate
before dilutions were made . Emulsionswere prepared with equalvolumes ofCFA. For all experiments
with guinea pigs and in initial experiments with rats, CFA was obtained from Difco Laboratories,
Detroit, Mich ., containing 0.5 mg/ml Mycobacterium butyricum . This was supplemented withM .
tuberculosis, H37Rv (Eli Lilly& Co .), 2 mg/ml for guinea pigs and0.5 mg/ml for rats (CFA-A) . In
later rat experiments the formula employed more emulsifer and different combinations of
mycobacteria (2 parts Bayol F to 1 part Aquaphor (Duke Laboratories, Inc ., South Norwalk, Conn .)
with 2.7 mg/mlM. butyricum (CFA-B), or with 0.5 mg/mlM. butyricum plusM. tuberculosis, H37Rv,
0.5 mg/ml (CFA-C) . Total vol of 0.1-0 .2 ml of emulsion were divided intradermally among multiple
sites . Rats received as an additional adjuvant 10' ° Bordetella pertussis organisms (special vaccine
product of Eli Lilly & Co .) subcutaneously into thedorsum of each hind foot.
Clinical Observations .
￿
Animals were weighed three times weekly and observed daily for signs of
muscular weakness which was graded according to the following score : 0, no definite weakness ; +,
weak grip or cry with fatigability ; ++, hunched posture with head down, movements uncoordinated,
and forelimb digits flexed ; and +++, severe generalized weakness, no cry or grip, tremulous, and
moribund .
Electrophysiological Observations . Electromyographs (EMG's) were recorded on a TECA-4
EMG instrument under Nembutal anesthesia (Abbott Laboratories, Chicago, Ill .) (35 mg/kg,
intraperitoneally [i .p .]) with percutaneously implanted stainless steel scalp electrodes . Supramaxi-
mal stimulation was applied to the sciatic nerve with recording from posterior distal hind limb
muscles and, when axillary stimulation was used in addition, from distal forelimb flexor muscles.A
single supramaximal response was measured and then followed by repetitive stimuli . Brieftrains of 2,
5, 10, and 20 responses/s were recorded superimposed, and then trains of 2, 5, 10, 20, and 50 re-
sponses/s were recorded by continuous write out . At stimulation rates of 50/s movement artifacts
were frequent and apparent decrements were often not reproducible . Only decrements found at all
rates of stimulation, on repeated recordings, andmeasuring at least 10% at stimulation rates of 2 or 5
/s, were considered significant . When a decrement of 10% or more was found (first compared with
fifth response), neostigmine methylsulfate (50-75 jug) was given i.p ., and serial studies were done
at 1-min intervals thereafter .
Antibody Assays . Rat sera were tested for antibodies to both eel and syngeneic rat skeletal
muscle AChR by immunoprecipitation using [,2'I ]toxin-lableled AChR in a modification of the
method ofPatrick et al . (5) . This assay, employing precipitation by rabbit antiratIgG of rat antibody
bound to [ ,l'I]toxin-labeled ACbR, measures antibody directed against sites on the AChR molecule
other than theACh-binding site . Control assays employed ["'I ]toxin without AChR. Guinea pig sera
were assayed by the Ouchterlony gel diffusion test .
Studies with Cobra Toxin . Cobra toxin purified by the method of Karlsson et al . (6) was
administered to rats to determine its clinical and electrophysiological effects . An intravenous dose of
200 pg/kg in saline (twice the lethal dose [LD,oo] for mice) induced a reproducible time-dependent
lethal response and was selected for electrophysiological studies . Three rats injected with toxin were
studied by repetitive stimulations at 2.5- to 5.0-min intervals until death, and a control rat injected
with saline was similarly studied for 20 min .
Results
Clinical Observations . Within 4 wk after a single injection of eel AChR
protein with adjuvant both rats and guinea pigs developed weakness charac-
terized by easy fatigability . The response to neostigmine (i.p .) was usually
one of partial motor improvement within 4 min . Relief was transient and some
severely weak animals failed to respond.V. A. LENNON, J. M. LINDSTROM, AND M. E. SEYBOLD
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Table I summarizes the dose response data from a single guinea pig experiment
and data pooled from two separate experiments with rats (using CFA-A and -C)
plus the experiment illustrated in Table 11 and Fig. 1 (using CFA-B). The
incidence and severity ofdisease induced with the highest dose was lower in both
species than that induced by doses one-half log lower, and probably reflects the
relative instability ofthe emulsion with highly concentrated AChR. Rechallenge
induced a higher incidence and greater severity of EAMG in both species, e.g.,
TABLE I
Incidence and Severity of EAMG in Guinea Pigs and Rats after a Single Challenge
with Eel AChR
Guinea pigs were observed for 30 days and rats up to 80 days. All rats received B. pertussis and
CFA-Aor -C except the nine indicated in Fig. 1 which received 350 pmol AChR in CFA-B.
Early, before day 16; late, generally after day 20.
$Parentheses indicate numbers survivingbeyond 20 days; some accidental deaths occurred.
EAMG of +/++ severity was induced in three of five guinea pigs by a repeated
dose of 1.1 pmol.
Weakness predominately affected the upperlimb, head andneck, and laryngeal
and respiratory muscles. A characteristic posture was noted in both species: the
animal's head tended to be low, often with its chin and elbows on the floor; the
back was exaggeratedly humped with the thighs partially abducted (Fig. 2).
Jerky movement of the head and forelimbs on attempted ambulation was
observed with severe EAMG. Incontinence of urine, inability to swallow, and, in
guinea pigs, tachypnea and cyanosis were sometimes observed as weakness
became more severe ; severe weakness of the hind limbs was uncommon. Early
signs ofweakness were loss ofcry and hypotonia associated with weakness ofthe
neck and forelimbs. In rats, the ability to grasp the bars ofa cage lid was rapidly
fatigable, and guinea pigs oftenfailed to retract their ears on painful stimulation.
Species
Dose
in
CFA
Number of
Total
animals with
Early*
clinical EAMG
Late* +
Maximum
++
severity
+++
pmol
Guinea pig 350 4/5 1 3(4)$ 2 2 0
110 5/5 0 5 0 1 4
35 1/5 0 1 1 0 0
11 1/5 0 1 1 0 0
3.5 1/5 0 1 1 0 0
1.1 1/5 0 1 1 0 0
0 0/4 0 0 0 0 0
Rat 350 21/23 21 15(15) 2 2 17
110 10/10 9 9(9) 0 2 8
55 2/2 2 2 0 1 1
35 8/9 6 6(8) 1 1 6
11 6/11 5 4 3 2 1
3.5 7/9 6 4 2 5 0
1.1 0/10 0 0 0 0 0
0 0/10 0 0 0 0 01368
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TABLE II
Occurrence of Weakness andEMGDecrements, and Titers ofAntibodies to Eel andRat
AChR in Rats Inoculated with Eel AChR and in Controls
Further details are given in footnote of Fig . 1 .
* Titers expressed as moles [1211]toxin-binding sites precipitated per liter of serum .
$ Accidental death .
§ No significant decrement wasfound in any of four similar control rats tested between days 20 and
55 .
Inoculum and rat no . Day
tested
Weakness
score
EMG
decrement
at 5cps
Titer of antibody toAChR*
eel x 10 -IM rat x 10 - '°M
AChR in CFA-A
1 9 0 0 4.8 < 1 .0
16 0 0 - -
24 0 0 14 1.6
43 0 0 - -
2 9 + 21 - -
15 0 11 - -
24 0 0 4.1 <1 .0
43 + 0 - 14
3 9 + 33 - -
16 0 0 - -
23 0 0 29 5.4
4$ 9 0 0 - -
15 0 0 - -
AChR in CFA-B
1 8 ++ 35 - -
2 9 ++ 33 5.4 < 1 .0
15 0 3 - -
23 0 0 56 11
34 +++ - - 13
3 9 0 9 6.3 < 1 .0
10 + 11 - -
15 0 0 - -
23 + 41 - -
4 8 + 14 8.7 <1.0
15 0 0 - -
24 0 0 110 15
43 ++ 0 - -
49 ++ 0 65 18
5 10 ++ 32 - -
15 0 0 - -
24 0 0 110 17
43 + 0 74 17
6 8 + 33 4.0 1.0
15 0 0 - -
24 0 0 80 13
35 + - - 17
7 7 +++ - - -
8 9 ++ 38 - -
15 0 0 - -
24 0 0 - -
9 9 + 11 6.0 < 1.0
CFA-13 alone
1 10 0 3 <0.001 <1.0
15 0 0 - -
27 0 -§ <0.001 <1.0
2 10 0 0 <0.001 <1.0
15 0 0 - -
27 0 - <0.001 < 1.0
3 10 0 0 <0.001 < 1.0
15 0 0 <0 .001 < 1.0
27 0 - <0.001 < 1.0
4 10 0 0 <0.001 < 1 .0
15 0 0 <0 .001 <1.0
27 0 - <0.001 < 1 .0V. A . LENNON, J . M. LINDSTROM, AND M. E. SEYBOLD
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FIG. 1 .
￿
Weight changes (tSD) recorded in 10 noninoculated rats (O-O) compared with rats
inoculated with 350 pmol of eel AChR in two different CFA preparations (CFA-A, A-", four
rats) and (CFA-B, N-", nine rats) . Five rats received CFA-B without AChR ("-" ), Two
of the four recipients of AChR in CFA-A had transient early weakness (days8 and 9) of mild
degree (+); none were reinoculated. The more potent CFA-B caused adjuvant arthritis (com-
mencing day 11, peaking days 17-23 and resolving by day 25) which may have accounted for
some early weight loss. All recipients ofAChR in CFA-B had early weakness (+/+++ ; mean
onset day, 8) ; three died and the remaining six recovered completely (mean recovery day, 12) .
On day 19 the six survivors were reinoculated
￿
All surviving rats in both groups which
received AChR had a second episode of weakness commencing between days 23 and 35 and
progressing to death . Table II documents the severity of weakness and electrophysiological
andantibody dataontheserats.
In rats the digits of the forelimbs became flexed and failed to extendwhen the rat
was placed on a flat bench. Neck muscle weakness prevented the animals from
reaching up for food or water, and excessive growth of the teeth, which occurred
only in rats with EAMG, suggested impairment of the muscles of mastication.
Weight loss at this stage could be delayed by placing soft food within easy reach
of the animals . At the height of the severity ofEAMG in rats, characteristic signs
of chronic respiratory disease often became manifest as porphyrin staining of
nasal secretions and tears. Loud respiratory noises, sometimes observed in the
absence of overt respiratory distress or necropsy evidence of gross lung pathol-
ogy, may have been due to laryngeal paralysis . Signs of chronic respiratory dis-
ease disappeared when muscular strength was regained .
Two distinct episodes of weakness, accompanied by weight loss, were observed
in rats, especially with large doses of AChR (Table I and Fig . 1) . The first was
acute in onset, commencing most often between day 7 and 12, and was usually
transient with apparent full recovery of strength by days 11-15 . The second
episode, one of progressive weakness, began most often between days 26 and 35
and was usually preceded 1-2 days by weight loss andsigns of chronic respiratory
disease which worsened with time . In guinea pigs, numerous relapses ofweakness1370
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FIG. 2.
￿
Postures characteristic ofEAMG in a ratand guinea pig . Note the lowhead with chin
andelbowson thefloor, hunchedback,abducted thighs,andflexeddigits .V . A . LENNON, J . M . LINDSTROM, AND M . E . SEYBOLD
￿
1371
were observed and often were associated with sudden stresses such as venesection
or extensive shaving for skin testing . All seven guinea pigs inoculated with 600
pmol of Torpedo californica AChR developed relapsing signs of EAMG which
became severe and progressive after day 42 .
Electrophysiological Observations .
￿
No significant decremental responses to
repetitive stimulation were found in any control animal inoculated with adjuvant
norin anyanimal which had not developed clinical signs ofEAMG . In guinea pigs
clinically severe weakness was frequently observed without demonstrable EMG
abnormalities . In rats, decremental EMG patterns were demonstrable at the
peak of clinical weakness, and the decrement lessened with clinical signs of
improvement (Table II) . In the experiment illustrated in Fig . 1 and Table 11,
decrements were found in 10 of 12 rats tested after inoculation with AChR .
Decrements of action potential, when present, were sometimes demonstrable
only in the forelimbs, were always reproducible, and were repaired with 6-13 min
after i.p . injection of neostigmine, the repair lasting less than 3 h (Fig . 3) .
The smallest response generally occurred with the fourth or fifth stimulus and
often increased slightly thereafter . Postactivation facilitation and exhaustion
FiG . 3 .
￿
(top) Typical decrementing EMG response of a rat with clinical EAMG. (middle)
Post-activation facilitation lasted 1 min, followed by return of the decrement at 2 min and ex-
haustion at 4 min. (bottom) Repair ofdecrement by prostigmine lasted less than 3 h .1372
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were demonstrable (Fig . 3) . Only 1 of 10 surviving rats had a significant
decrement (11%) when studied 15-16 days after inoculation at which time none
was clinically weak . One rat developed a decrement on day 23, which was 4 days
after a second inoculation (Fig . 2 and Table 11) . Three rats studied later, when
weight loss and progressive weakness were present, showed no decrement .
Studies with Cobra Toxin.
￿
Naja naja siamensis toxin was chosen to examine
in rats the clinical and electrophysiological effects of in vivo blockade of nicotinic
AChR . All four nonanesthetized rats observed after intravenous injection of 200
,ug toxin/kg showed signs of weakness 7-10 min after injection, namely : inability
to raise the head, hunched posture, forelimb weakness, and inability to extend
the forelimb digits . The rats were moribund at 20 min and complete respiratory
paralysis ensued at approximately 30 min .
No significant decrement or change in amplitude of a single response occurred
in the rat injected with saline . The three rats injected with toxin showed a
progressive decline in amplitude of the response to stimulation . This decrease
was first noted 10 min after injection (response amplitudes 84, 62, and 77% of
the initial amplitude) . Amplitudes were even lower at 20 min (17, 16, and 20% of
initial values), and at death they were reduced to 10% of their initial values (12,
7, and 8%) . Decremental responses were not found until 10-13 min after injection
(11, 17, and 7% decrements) . The smallest response occurred with the fourth or
fifth stimulus and sometimes increased slightly thereafter . Significant decre-
ments developed in all three rats, but the percent decrement did not progress
with time (maximum percent decrement, 28) .
Antibody Assays . Sera from rats inoculated with eel AChR contained
antibody against AChR from both eel electric organ and rat skeletal muscle
(Table 11), but not against ' 251-labeled toxin. The titer of autoantibody was about
1/10,000 that of antibody to eel AChR . Antibody titers are expressed as moles of
toxin-binding sites precipitated per liter of serum. Since AChR is a dimer or
trimer, these titers are two- to threefold the molar concentration of antibody .
Antibody to eelAChR was demonstrable by the relatively insensitive method of
double diffusion in agar in -y-globulin fractions prepared from guinea pig sera 4
wk after inoculation .
Discussion
EAMG results from an autoimmune response to nicotinic AChR induced by
heterologous AChR . To dateEAMG has been induced in four species by inocula-
tion with AChR prepared from the electric organ of the eel Electrophorus elec-
tricus : rabbit (1), goat (J . M. Lindstrom, unpublished observation), rat, and
guinea pig, and in the latter also with AChR from Torpedo californica . Although
remote phylogenetically, the electric organ AChR must retain sufficient anti-
genic homology to AChR of mammalian skeletal muscle to break immunological
tolerance to the autologous antigen . The availability of inbred strains of rats and
guinea pigs will allow detailed immunogenetic analysis ofEAMG to be done, and
these small species have the advantage of requiring only small quantities of
AChR for disease induction .
All species in which EAMG has been induced have produced circulating
antibody toAM . The concept that anti-AChR antibody may cause defectiveV. A . LENNON, J. M. LINDSTROM, AND M. E. SEYBOLD
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neuromuscular transmission in EAMG is supported by the fact that immune
rabbit sera, but not normal rabbit sera, produced in vitro a functional block of
ACh responses of both electric organ cells (5) and cultured rat myoblast cells (1) .
The presence of antibody against syngeneic rat muscle AChR in the serumof rats
with EAMG documents the existence of autoimmunity in this experimental
disease . The autoantibody measured in this study was directed at sites on the
AChR molecule other than the ACh-binding site (which was occupied by
radiolabeled toxin) . Antibodies against the site on the AChR molecule which
binds ACh comprise only a small fraction of the total antibody to AChR in the
serum of animals with EAMG (5) . If anti-AChR antibody is to be incriminated in
the pathogenesis of EAMG, an explanation is required for its apparently minor
specificity for the receptor's ACh-binding site . It might be envisaged that the
presumed pathogenic species of antibody is directed against some functionally
important part of the receptor molecule other than the ACh-binding site or that
antisite antibody is selectively removed from the circulation by adsorption in
vivo of ACh-binding sites in muscles.
The occurrence of myasthenic-type weakness in some guinea pigs and rats
without accompanying EMG changes is not readily explainable . In preliminary
studies, direct measurement with microelectrodes has shown amplitudes of
miniature end-plate potentials in rats with EAMG to be reduced in all stages of
weakness (E . Lambert, S . Bevan, and S. Heinemann, unpublished observations) .
In order to directly investigate the clinical and electromyographic effects of in
vivo blockade of muscleAChR, we treated rats with purified cobra toxin which is
known to block nicotinic AChR (7) . Both weakness and a decrementing EMG
were induced. Toxin caused a progressive decrease in amplitude of the initial
EMG response to supramaximal stimulation . This was possibly due to complete
inactivation ofmany motorend-plates by the overwhelming amount of toxinused.
The relatively few end-plates left with a marginal safety factor for firing would
account for the decrementing responses noted . A similar but smaller decrease in
amplitude was also recorded in EAMG .
Evidence implicating autoimmunity in MG has been well documented .
Autoantibodies, especially to muscle striations (8) and thyroid (9), are more
frequent in MG than would be expected by chance, as is the incidence of other
putative autoimmune diseases (2) . Thymic abnormalities in the form of
hyperplasia with germinal centers and thymoma are common in patients with
MG (10) . Thymectomy (11) and immunosuppressive therapy (12) can be
beneficial in treating MG, and newborns of myasthenic mothers sometimes
exhibit transient signs of myasthenia which last for approximately as long as
maternal antibody persists in the newborn (10) . Reduction in the number of
binding sites forACh in biopsied nerve-muscle junctions from patients with MG
(13) lends support to the hypothesis that antibody may be blocking AChR (2, 3) .
Almon and co-workers (14) reported that serum globulins from 5 of 15 patients
withMG competed with radiolabeled toxin forthe ACh-binding site on rat muscle
AChR. Moreover, we recently have found antibody to human AChR in 72 of 74
sera tested from patients with MG . 2
EAMG is similar toMG in many respects. Weakness in both experimentally in-
duced myasthenia and spontaneous MG of humans and dogs (15) frequently
affects muscles of the head and neck, upper limbs, and respiration; is charac-1374
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terized by easy fatigue ; and is relieved by anticholinesterases . Electrophysio-
logically, in both conditions a decrementing response is induced by fairly slow
rates of stimulation (2-5/s), and impairment of electrophysiological activity
does not uniformly involve all muscles even when weakness is quite severe (16) .
The amplitude of the response progressively diminishes to the fourth or fifth
response and then plateaus or increases slightly . Rapid repetitive stimulation
initially repairs the defect (postactivation facilitation), but after 2-6 min, the
defect is accentuated (exhaustion) . Repair of the electrical defect also is achieved
with anticholinesterases . Reduction in amplitude of miniature end-plate poten-
tials is an important point of similarity between EAMG (E . Lambert, S. Bevan,
and S. Heinemann, unpublished observation) andMG (17) . Finally, antibody to
AChR is demonstrable in the serum of animals with EAMG and patients with
MG (reference 14 and footnote 2) . These data confirm the validity ofEAMG as a
model for the study of MG and suggest that a common immunopathogenic
mechanism may underlie both diseases.
Summary
Immunization of animals with acetylcholine receptor (AChR) protein from the
electric organs of Electrophorus electricus and Torpedo californica induces an
autoimmune response to the AChR of mammalian skeletal muscle . Rats and
guinea pigs develop experimental autoimmune myasthenia gravis (EAMG) after
a single inoculation with small quantities of AChR and adjuvant. The incidence
and severity of disease appears to depend on the dose of AChR and stability of
the emulsion .EAMG is strikingly similar to myasthenia gravis (MG) ofman in its
clinical picture and its electrophysiological abnormalities . The presence of anti-
bodies to syngeneic rat muscle AChR in the serum of rats withEAMG documents
the existence of autoimmunity in the experimental disease. Acommon immuno-
pathogenesis is suggested for both EAMG and MG .
The authors thank Janet Clark, Brett Einarson, and Beki Baergen for excellent technical assistance
and Eli Lilly & Co ., Indianapolis, Ind ., for gifts of Bordetella pertussis and Tylosin .
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